Your search for bevacizumab returned 18 results

Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation.

At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab

Alymsys is a vascular endothelial growth factor inhibitor.

Vegzelma is a vascular endothelial growth factor inhibitor.

Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first

The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.

Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.

There was no improvement in overall survival with bevacizumab.

Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.